S'abonner

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial - 02/10/15

Doi : 10.1016/S1470-2045(15)00135-7 
Rajendra Badwe, ProfMS a, , Rohini Hawaldar, BSc b, Nita Nair, MCh a, Rucha Kaushik, MS a, Vani Parmar, ProfMS a, Shabina Siddique, MSc b, Ashwini Budrukkar, ProfMD c, Indraneel Mittra, ProfFRCS a, Sudeep Gupta, ProfDM d
a Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India 
b Breast Cancer Working Group, Tata Memorial Centre, Mumbai, India 
c Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India 
d Department of Medical Oncology, Tata Memorial Centre, Mumbai, India 

* Correspondence to: Prof Rajendra A Badwe, Tata Memorial Centre, Parel, Mumbai 400012, India Correspondence to: Prof Rajendra A Badwe Tata Memorial Centre Parel Mumbai 400012 India

Summary

Background

The role of locoregional treatment in women with metastatic breast cancer at first presentation is unclear. Preclinical evidence suggests that such treatment might help the growth of metastatic disease, whereas many retrospective analyses in clinical cohorts have suggested a favourable effect of locoregional treatment in these patients. We aimed to compare the effect of locoregional treatment with no treatment on outcome in women with metastatic breast cancer at initial presentation.

Methods

In this open-label, randomised controlled trial, we recruited previously untreated patients (≤65 years of age with an estimated remaining life expectancy of at least 1 year) presenting with de-novo metastatic breast cancer from Tata Memorial Centre, Mumbai, India. Patients were randomly assigned (1:1) to receive locoregional treatment directed at their primary breast tumour and axillary lymph nodes, or no locoregional treatment, by a computer-generated block randomisation sequence (block size of four). Randomisation was stratified by site of distant metastases, number of metastatic lesions, and hormone receptor status. Patients with resectable primary tumour in the breast that could be treated with endocrine therapy were randomly assigned upfront, whereas those with an unresectable primary tumour were planned for chemotherapy before randomisation. Of the patients who had chemotherapy before randomisation, we randomly assigned patients who had an objective tumour response after six to eight cycles of chemotherapy. The primary endpoint was overall survival analysed by intention to treat. This study is registered with ClinicalTrials.gov, NCT00193778.

Findings

Between Feb 7, 2005, and Jan 18, 2013, of the 716 women presenting with de-novo metastatic breast cancer, we randomly assigned 350 patients: 173 to locoregional treatment and 177 to no locoregional treatment. At data cut-off of Nov 1, 2013, median follow-up was 23 months (IQR 12·2–38·7) with 235 deaths (locoregional treatment n=118, no locoregional treatment n=117). Median overall survival was 19·2 months (95% CI 15·98–22·46) in the locoregional treatment group and 20·5 months (16·96–23·98) in the no-locoregional treatment group (HR 1·04, 95% CI 0·81–1·34; p=0·79), and the corresponding 2-year overall survival was 41·9% (95% CI 33·9–49·7) in the locoregional treatment group and 43·0% (35·2–50·8) in the no locoregional treatment group. The only adverse event noted was wound infection related to surgery in one patient in the locoregional treatment group.

Interpretation

There is no evidence to suggest that locoregional treatment of the primary tumour affects overall survival in patients with metastatic breast cancer at initial presentation who have responded to front-line chemotherapy, and this procedure should not be part of routine practice.

Funding

Department of Atomic Energy, Government of India.

Le texte complet de cet article est disponible en PDF.

Plan


© 2015  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 16 - N° 13

P. 1380-1388 - octobre 2015 Retour au numéro
Article précédent Article précédent
  • Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
  • Marinus H J van Oers, Kazimierz Kuliczkowski, Lukáš Smolej, Mario Petrini, Fritz Offner, Sebastian Grosicki, Mark-David Levin, Ira Gupta, Jennifer Phillips, Vanessa Williams, Stephanie Manson, Steen Lisby, Christian Geisler, PROLONG study investigators
| Article suivant Article suivant
  • Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
  • Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, Jacob Schachter, Reinhard Dummer, Andrzej Mackiewicz, Daniil Stroyakovskiy, Kamil Drucis, Florent Grange, Vanna Chiarion-Sileni, Piotr Rutkowski, Mikhail Lichinitser, Evgeny Levchenko, Pascal Wolter, Axel Hauschild, Georgina V Long, Paul Nathan, Antoni Ribas, Keith Flaherty, Peng Sun, Jeffrey J Legos, Diane Opatt McDowell, Bijoyesh Mookerjee, Dirk Schadendorf, Caroline Robert

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.